| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/08923973.2013.780078 |
| P8608 | Fatcat ID | release_w7q7f7sh45dqhie2gxesvz65tu |
| P698 | PubMed publication ID | 23635029 |
| P50 | author | Reinhard Kandolf | Q84837539 |
| P2093 | author name string | Thorsten Lewalter | |
| Ernst Tönnesmann | |||
| P2860 | cites work | Complete heart block in chronic chloroquine poisoning | Q41920787 |
| Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials | Q41921005 | ||
| Chloroquine-induced cytosomes with curvilinear profiles in muscle | Q41927906 | ||
| Fatal antimalarial-induced cardiomyopathy: report of 2 cases | Q41928165 | ||
| Hydroxychloroquine: a treatable cause of cardiomyopathy | Q41928584 | ||
| Vacuolar myopathy associated with chloroquine, lupus erythematosus and thymoma. Report of a case with unusual mitochondrial changes and lipid accumulation in muscle | Q41929690 | ||
| Case records of the Massachusetts General Hospital. Case 11-2011. A 47-year-old man with systemic lupus erythematosus and heart failure | Q41933034 | ||
| Hydroxychloroquine-induced cardiomyopathy: a case report | Q41933255 | ||
| Experimental lesions of the nervous and muscular systems due to chloroquine: models of various storage dystrophies (author's transl) | Q41933747 | ||
| Images in cardiology. Chloroquine-induced transition from dilated to restrictive cardiomyopathy | Q41933857 | ||
| Morphologic Study of a Neuromyopathy Caused by Prolonged Chloroquine Treatment | Q41934936 | ||
| Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus | Q41935707 | ||
| Cardiotoxicity after low-dose chloroquine antimalarial therapy | Q41937566 | ||
| Chloroquine cardiotoxicity in long-term lupus therapy in two patients | Q41938083 | ||
| Restrictive cardiomyopathy secondary to hydroxychloroquine therapy | Q41939157 | ||
| Severe hydroxychloroquine myopathy | Q41940337 | ||
| Complete atrioventricular block following long term treatment with chloroquine | Q41940412 | ||
| New clinical and ultrastructural findings in hydroxychloroquine-induced cardiomyopathy--a report of 2 cases | Q41941843 | ||
| ELECTROCARDIOGRAM AFTER CHLOROQUINE AND EMETINE. | Q41942646 | ||
| Hydroxychloroquine and systemic lupus: a reappraisal | Q41942674 | ||
| VACUOLAR MYOPATHY: CLINICAL, HISTOCHEMICAL, AND MICROSCOPIC STUDY. | Q41942791 | ||
| Chloroquine-induced bull's eye maculopathy in rheumatoid arthritis: related to disease duration? | Q41943683 | ||
| Heart conduction disorders related to antimalarials toxicity: an analysis of electrocardiograms in 85 patients treated with hydroxychloroquine for connective tissue diseases | Q41943895 | ||
| Low blood concentration of hydroxychloroquine is a marker for and predictor of disease exacerbations in patients with systemic lupus erythematosus | Q41944460 | ||
| The cardiac safety of chloroquine phosphate treatment in patients with systemic lupus erythematosus: the influence on arrhythmia, heart rate variability and repolarization parameters | Q41944686 | ||
| Images in cardiovascular medicine. Contrast-enhanced magnetic resonance imaging of a patient with chloroquine-induced cardiomyopathy confirmed by endomyocardial biopsy | Q41944714 | ||
| Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia | Q41945547 | ||
| Hydroxychloroquine-induced restrictive cardiomyopathy | Q41945578 | ||
| Chloroquine abuse and heart block in Africans | Q41946296 | ||
| Hydroxychloroquine-induced cardiotoxicity in a 39-year-old woman with systemic lupus erythematosus and systolic dysfunction | Q41946807 | ||
| Cardiomyopathy under treatment with hydroxychloroquine disclosed by complete auriculoventricular block | Q42559738 | ||
| Complete heart block following chronic chloroquine treatment | Q43504581 | ||
| 42-year-old man with discoid lupus and progressive weakness | Q46201165 | ||
| Neuronal ceroid lipofuscinosis: an ultrastructural, genetic, and clinical study report | Q48921907 | ||
| Conduction disorder and QT prolongation secondary to long-term treatment with chloroquine. | Q50971000 | ||
| Complete heart block due to chronic chloroquine toxicity managed with permanent pacemaker | Q28331954 | ||
| Cardiac toxicity secondary to long term treatment with chloroquine | Q28360029 | ||
| Restrictive cardiomyopathy caused by chloroquine | Q28378730 | ||
| Clinical utility of LC3 and p62 immunohistochemistry in diagnosis of drug-induced autophagic vacuolar myopathies: a case-control study | Q28482758 | ||
| Continuation of long term treatment with hydroxychloroquine in systemic lupus erythematosus and rheumatoid arthritis. | Q33565136 | ||
| Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy | Q34158360 | ||
| Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy | Q34162386 | ||
| Cardiac damage from chronic use of chloroquine: a case report and review of the literature | Q34774772 | ||
| STUDIES ON THE CHRONIC TOXICITY OF CHLOROQUINE (SN-7618) | Q35307420 | ||
| Long-term effectiveness of antimalarial drugs in rheumatic diseases | Q35547553 | ||
| Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients | Q35636940 | ||
| Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature | Q35744085 | ||
| Cardiomyopathy related to antimalarial therapy with illustrative case report | Q36521126 | ||
| Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases | Q36596360 | ||
| The heart and cardiovascular manifestations in rheumatoid arthritis | Q36596365 | ||
| Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review | Q37356697 | ||
| Cardiac pathology of systemic lupus erythematosus. | Q37533906 | ||
| Hydroxychloroquine: from malaria to autoimmunity | Q37827403 | ||
| The role of antimalarial agents in the treatment of SLE and lupus nephritis | Q37947108 | ||
| Acute left ventricular failure in a patient with hydroxychloroquine-induced cardiomyopathy | Q38863139 | ||
| Experimental chloroquine myopathy | Q39431908 | ||
| Histological and ultrastructural findings in chloroquine-induced cardiomyopathy. | Q40456057 | ||
| [Complete auriculoventricular block during chloroquine treatment]. | Q40462987 | ||
| Incidence of myopathy in patients treated with antimalarials. A report of three cases and a review of the literature | Q40499065 | ||
| Clinical pharmacokinetics of slow-acting antirheumatic drugs | Q40619935 | ||
| Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements | Q41192707 | ||
| Cationic amphiphilic drug-induced phospholipidosis | Q41376259 | ||
| A case of chloroquine-induced cardiomyopathy that presented as sick sinus syndrome | Q41438570 | ||
| Morphological study of peripheral nerve changes induced by chloroquine treatment | Q41912883 | ||
| Chloroquine neuromyotoxicity. Clinical and pathologic perspective | Q41913997 | ||
| Diagnosis of chloroquine cardiomyopathy by endomyocardial biopsy | Q41914228 | ||
| Heart transplantation in a patient with chloroquine-induced cardiomyopathy | Q41914581 | ||
| Cardiovascular effects linked to the use of chloroquine | Q41916448 | ||
| Chloroquine cardiotoxicity: clinicopathologic features in three patients and comparison with three patients with Fabry disease | Q41916852 | ||
| Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology | Q41917354 | ||
| P433 | issue | 3 | |
| P921 | main subject | chloroquine | Q422438 |
| cardiomyopathy | Q847583 | ||
| P304 | page(s) | 434-442 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Immunopharmacology and Immunotoxicology | Q4200316 |
| P1476 | title | Chloroquine cardiomyopathy - a review of the literature | |
| P478 | volume | 35 |
| Q95840784 | A Bitter Taste in Your Heart |
| Q49383501 | Antimalarial-induced cardiomyopathy: a systematic review of the literature |
| Q91992733 | COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs |
| Q98620978 | Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases? |
| Q94559419 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol |
| Q90575837 | Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic |
| Q97550264 | Cardiovascular Considerations for the Internist and Hospitalist in the COVID-19 Era |
| Q99610680 | Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports |
| Q92128011 | Cardiovascular complications in COVID-19 |
| Q96017828 | Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients |
| Q38360827 | Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases |
| Q34198175 | Chloroquine cardiomyopathy: beyond ocular adverse effects |
| Q54218397 | Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. |
| Q98779013 | Drug Interactions of Psychiatric and COVID-19 Medications |
| Q38896720 | Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules |
| Q90059150 | How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) |
| Q38285841 | Hydroxychloroquine in children with interstitial (diffuse parenchymal) lung diseases |
| Q39031764 | Hydroxychloroquine in systemic lupus erythematosus (SLE). |
| Q55042425 | Hydroxychloroquine-induced cardiomyopathy and heart failure in twins. |
| Q89181689 | Hydroxychloroquine-induced cardiomyopathy in a patient with limited cutaneous systemic sclerosis |
| Q99610879 | Insights on the evidence of cardiotoxicity of hydroxychloroquine prior and during COVID-19 epidemic |
| Q39557090 | Myocarditis associated with Plasmodium vivax malaria: a case report |
| Q38734155 | No histologic evidence of foetal cardiotoxicity following exposure to maternal hydroxychloroquine |
| Q39392030 | Novel role of miR-29a in pancreatic cancer autophagy and its therapeutic potential |
| Q50882478 | Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus. |
| Q28077676 | The effect of malaria and anti-malarial drugs on skeletal and cardiac muscles |
Search more.